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Binding and beyond: what else can G-quadruplex ligands do? 
Michael P. O’Hagan,*[a] Juan C. Morales[b] and M. Carmen Galan*[a] 
 
Abstract: G-quadruplexes (G4) are four-stranded structures formed 
from guanine-rich oligonucleotides. Their defined 3D structures and 
polymorphic nature set them apart from classical nucleic acid 
morphology and suggest a range of potential applications in the 
development of functional materials. Meanwhile, the occurrence of G4 
across the genomes of animals, plants and pathogens suggests roles 
for these structures in biology that may be exploited for therapeutic 
effect. Hundreds of G4 ligands are reported to bind these sequences 
with high specificity and affinity, but such ligands can also be 
engineered to do more than simply associate with G4 in a 
straightforward host-guest fashion. Ligands have been developed that 
can switch G4 topology, direct the selective covalent modification of 
nucleic acid structures, or respond to external stimuli to permit 
spatiotemoral control of their activity. Herein we survey the main 
themes of such “value-added” G4 ligands and consider the 
opportunities and challenges of their potential applications. 
1. Introduction 
Nucleic acids are well known for their ability to form a wide range 
of higher-order structures,[1–3] a property that allows these 
molecules to fulfil a wide range of fascinating and important 
functions. In biology, the DNA double helix provides the means of 
information storage for the whole of life.[4] Meanwhile, RNA is the 
basis of one of nature’s most impressive machines, the ribosome, 
that so elegantly translates structure to function.[5] G-
quadruplexes (G4) belong to this fascinating array of nucleic acid 
structures, having distinct properties of their own that have piqued 
interest across scientific disciplines interested in their chemistry, 
biology and applications.[6]  
1.1 G-quadruplexes: structure and history 
G4s are four-stranded structures formed from guanine rich 
nucleic acid sequences.[7] The underlying motif of this structure is 
the G-tetrad, formed from the self-association of four guanine 
residues in a square planar arrangement, stabilized by Hoogsteen 
hydrogen bonding and coordination to a central metal cation. The 
folding of the underlying oligonucleotide strand causes the 
stacking of these tetrads to form the quadruplex (Figure 1). 
Notably, these structures exhibit polymorphism, with the folding 
conditions and the nature of the intervening loop sequences 
determining the overall topology. For example, the human 
telomeric G4 sequence (based on TTAGGG repeats) is observed 
to form parallel, antiparallel and hybrid conformations depending 
on the folding conditions, e.g. the buffer ionic strength, the identity 
of the metal cation, or the presence or absence of crowding 
agents.[8–10] Such structures can be elucidated by a variety of 
methods, though a particularly distinctive feature is the circular 
dichroism signature of the different types (Figure 1).[11] In each 
case, diagnostic bands arise from the syn/anti conformations of 
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the glycosidic bond angles in the chiral structure. In the parallel 
structure all guanosines adopt an anti conformation whilst the 
antiparallel and hybrid topologies feature syn conformations at 
certain residues. Antiparallel G4s may be further divided into two 
types: the basket conformation (as in Figure 1b) characterized by 
two lateral loops (top tetrad) and one diagonal loop (lower tetrad). 
The alternative chair conformation contains three lateral 
loops.[12]A detailed examination of G4 polymorphism is beyond 
the scope of this article, but the interested reader is directed to 
many excellent reviews and studies on the topic.[7,11,13–17]   
Clues to the existence of G4 were first uncovered during the 
1970s and 1980s, when X-ray diffraction demonstrated the 
formation of helical structures from self-assembly of polyguanylic 
acid,[18,19] and Sen and Gilbert observed the self-association of G-
rich DNA into four-stranded structures in monovalent salt 
buffer.[20] Even so, it was not until detailed structures were solved 
unambiguously by X-ray crystallography[21] and NMR[22,23] in the 
early 1990s that the field of G4 research took off in earnest. Since 
then, an explosion of interest in the structure and function of G-
quadruplexes can be observed throughout the scientific literature 
which has been aided by the exponential progress in 
technological developments over the last two decades. Advances 
in structural biology, have allowed the intricacies of these folded 
structures to be explored in exquisite detail in solution[24–27] and 
even in live cells.[28] The maturity of bioinformatics allows the 
mining of whole genomes to locate potential G4-forming 
sequences, identifying hundreds of thousands of occurrences in 
the genomes of humans and other organisms,[29–32] whilst cutting-
edge sequencing methods have validated the existence of such 
quadruplexes experimentally in a number of species.[33]  
Meanwhile, progress in biology has delivered ever increasing 
evidence for the role of these sequences in life, from organism 
development, through to epigenetic regulation and their role in 
health and disease.[34,35] Indeed, various therapeutic hypotheses 
have been proposed, such as targeting G4s to inhibit the 
transcription of oncogenes[36,37] (Figure 2) or by targeting the G4 
sequence in chromosome telomeres.[38] But this does not confine 
interest in G4 to the biological community alone; the precise 
folding of such structures into well-defined shapes and their 
polymorphism, that can be controlled by different conditions and 
stimuli, point to exciting applications of these structures away from 
the biological milieu in the development of new responsive 
enzymes,[39–42] switches,[43,44] and functional materials.[45] 
1.2. G4 as nanodevices 
The polymorphic secondary structure of both the G4 and its sister 
strand, the cytosine-rich i-motif,[3] suggests a range of 
applications of these structures in the development of functional 
materials. Many strategies for exerting control of nucleic acid 
secondary structure have been explored. Systems have been 
designed to be responsive to a variety of stimuli including light,[47] 
pH,[48] redox processes[49,50] and the addition and sequestration of 
metal ions.[39] In particular, the sensitivity of the G4 to the 
presence of metal ions and the i-motif to pH have been exploited 
many times as the basis for the design of DNA derived switches, 
and progress in this area has been extensively reviewed.[43,44,51,52] 
In Section 2, we focus instead on the use of small molecule 
 
Figure 1: (a) Chemical structure of a G-tetrad (1) showing 
Hoogsteen hydrogen bonds between four guanine residues. 
The sugar-phosphate backbone is denoted R. (b) three 
topologies adopted by G4 nucleic acids (left) and their 
respective circular dichroism signatures (right). The central 
cations have been omitted for clarity. Color code of guanosine 
glycosidic bond conformations: pale blue = anti; dark blue = 
syn. CD spectra were collected by the authors using model G4 
sequences in appropriate buffer.[46] 






ligands as triggers to control G4 structure and function. Towards 
the development of nanodevices, ligands are an interesting 
means to not only control the formation of G4, but also to toggle 
G4s between different conformations.[53] Since such small 
molecules can themselves be designed to be stimuli-responsive, 
they may themselves serve as fuels for the reversible 
manipulation of G4 systems.[54,55] In contrast to engineering the 
responsive functionality into the nucleic acid itself, an approach 
frequently adopted for the reversible control of biomolecules,[56] 
such supramolecular approaches have the advantage that pre-
modification of the oligonucleotide is not necessary, allowing 
possible applications in situations, such as medicine, where this 
is not desirable or possible. In taking this approach, we do not 
mean to divert attention from the impressive body of work that 
achieves G4 regulation by the pre-incorporation of unnatural 
functionality, but we aim to provide a complementary picture and 
highlight the potential of ligand-driven approaches for regulation 
of G4. 
1.3. G4 as therapeutic targets 
The significant level of interest in G4 partly stems from its potential 
as a therapeutic target.[36,38,57–59] Indeed, G4-forming DNA and 
RNA sequences are not confined to the human genome but also 
observed in a host of other organisms including plants,[60] 
bacteria,[61] viruses[62–64] and parasites.[65–67] This provides many 
potential opportunities to exploit G4 for the development of new 
therapeutic strategies. Indeed, our own research groups and 
many others have reported work driven towards the identification 
of new G4 ligands as the basis of anticancer[68,69] and 
antiparasitic[65,70] therapies. The vast majority of G4 ligands 
employ rigid aromatic heterocyclic frameworks that are designed 
to π-stack onto the large surface of the G-tetrads.[71]  Cationic 
character (for aqueous solubility and electrostatic interactions 
with negatively charged nucleic acids) is often introduced by 
conjugation of these cores to basic amino residues, to 
quaternized ammonium or pyridinium moieties, or to transition 
metal cations. Though the majority of G4 ligands contain this 
design feature, there are notable exceptions that are not cationic, 
such as the neutral macrocycle telomestatin (see Section 2.3) or 
N-methyl mesoporphyrin IX (see Section 2.2) which is negatively 
charged. Ligands may also be designed to target the G4 loops or 
grooves as well as the planar tetrads. Chemical structures and 
associated activity data for approximately one thousand ligands 
are currently curated in the online G4 ligand database, and new 
chemotypes are frequently reported.[72]. Progress towards  the 
goal of G4-targeted therapy is frequently documented and it is not 
our intention to cover general G4 ligand design principles in this 
review, since they are covered comprehensively 
elsewhere.[58,71,73–79] However, over the course of our endeavors 
in G4 ligand chemistry we have become more deeply interested 
in the potential of ligands to do more than simply bind G4 with the 
aim of enhancing their stability or extending their lifetime in vivo. 
Indeed, the field has recently taken steps towards engineering G4 
ligands that exert different kinds of control on G4 that could be 
exploited toward biological and therapeutic ends. Such 
approaches harness the selectivity of G4-binding chemotypes to 
trigger a further molecular event, such as modification of the G4 
by alkylation[80] or oxidation,[81] or as the basis for the localized 
generation of singlet-oxygen by photosensitization.[82] 
Furthermore, a small number of responsive G4 ligands have also 
been described. In these cases, the activity of the ligand is 
unlocked in response to a stimulus, such as photoirradiation[83] or 
the redox environment.[84] Such approaches allow an additional 
level of spatiotemporal control over the system, and therefore 
potential to act as starting points for a new generation of smart 
drugs where activity can be controlled with greater precision to 
minimize off-target side effects.[85,86] In Sections 3 and 4 we aim 




Figure 2: One of several possible mechanisms of oncogene suppression by targeting G4 DNA with small molecules. Induction of 
the G4 fold in the gene promoter by the stabilizing ligand inhibits the binding of RNA polymerase and transcription factors leading to 
downstream silencing of the gene. The folded G4 structure may also interfere with transcription factor binding, and examples of G4-
targeting molecules that up-regulate certain genes are also known.[37] 







The two applications discussed above, namely exploiting G4 in 
the development of new nanodevices and therapies, are united 
by a common theme: the need to exert control on the formation of 
the G4 structure and the potential of ligands to afford such control. 
In both cases, ligands that induce effects in G4 beyond simply 
binding to the native structure show potential to control G4 in 
interesting ways, particularly in cases where the activity of such 
ligands can itself be regulated by an external stimulus. In this 
report, we aim to provide a critical examination of developments 
in these areas to spark further interest in the development of such 
“value-added” G4 ligands. Our aim is to focus more on the 
different effects of the ligands, rather than to provide a 
comprehensive almanac of structures, biophysical results and 
thermodynamic data (though such data are quoted when 
appropriate). This is not to understate the importance of these 
parameters in G4 ligand design, and the interested reader will be 
able to find full details in the cited publications. But we hope that 
our account will help provide an overall picture of the state-of-the-
art in this area and will allow more general considerations and 
effects to be reviewed in a holistic fashion. Several G4 sequences 
are referred to throughout the review, commonly employed as 
model systems by researchers investigating G4 ligand binding; 
those that feature in the text are shown in Table 1. 
2. Ligand-driven switching of G4 folding – a 
pathway to novel nanodevices? 
2.1. Introduction 
The possibility of exploiting the self-assembly properties of 
nucleic acid structures as the basis of nanodevices has been 
around for some time, with pioneering examples exploiting 
hybridization strategies to exert control in DNA conformation 
employing complementary oligonucleotides as fuel.[88–90] In 2003, 
Alberti and Mergny reported the first example of a G4-based 
nanomachine, which relies on such a hybridization strategy.[87] A 
reversible folding/unfolding G4 device was produced that could 
be switched over eleven cycles without observable photofatigue 
by addition of appropriate complementary DNA strands. The 
effective diameter of the G4 sequence changes from 1.5 nm in 
the folded state to 7 nm in the single stranded form (Figure 3). 
Such properties could possibly be exploited to position molecular 
cargo or exert force at the molecular level. However, the need for 
repeated additions of two different DNA fuels and the generation 
of the CG waste product are drawbacks of this approach. More 
recently, systems have been developed that circumvent the need 
for a chemical fuel by incorporation of responsive functionality in 
the DNA sequence itself, permitting the stimuli-driven changes in 
folding without need for external fuel. Ogasawara and Maeda 
have reported the incorporation of a photoresponsive nucleobase 
into an oligonucleotide sequence that allows the reversible folding 
and unfolding of G4 triggered by different wavelengths of UV-
light.[91] More recently, the Heckel group have demonstrated the 
photoresponsive formation of an intermolecular G-quadruplex by 
incorporation of azobenzene functionality into the backbone of 
guanosine tetramers.[92] The Tucker group have reported a bis-
anthracene-functionalised G4 thrombin-binding aptamer whereby 
photocrosslinking of the anthracene moieties can control the 
binding, and therefore activity, of thrombin.[93] Though many 
exciting applications of these elegant approaches to regulating 
G4 structure can be envisaged, the drawback in these cases is 
the need to rely on pre-incorporation of unnatural functionality into 
the oligonucleotide. Complementary applications, where such a 
modification of the underlying DNA sequence is undesirable, 
could be achieved by supramolecular ligand-driven 
approaches.[47] Since such ligands can be themselves designed 
Table 1: Model G4 sequences referred to in this review 






c-kit 1 d[GGGAGGGCGCTGGGAGGAGGG] 
c-kit 2 d[GGGCGGGCGCGAGGGAGGGG] 
 
Figure 3: The G4-derived nanomachine developed by Alberti 
and Mergny. Addition of the C-strand fuel drives the unfolding 
of the G4 to allow hybridization to form the CG duplex. The 
process is reversed by adding G-strand fuel which displaced 
the G4-forming sequence from the C-strand to regenerate the 
original folded G4 and the CG duplex as a waste product.[87] 






to be stimuli responsive, their effects can be controlled by a 
variety of triggers, affording additional levels of spatiotemporal 
control likely to be desirable in the development of functional 
materials. 
 
As mentioned previously, we have chosen to focus specifically on 
small molecule ligands as G4 switching triggers. For a 
comprehensive review on other supramolecular triggers as the 
basis of G4 nucleic acids the reader is directed to several previous 
works.[43,44,51,52] For the most part, we have focused specifically on 
molecules that induce switches in pre-formed G4 topology in the 
presence of metal ions, rather than transitions between G4 and 
 
Figure 4: Ligands reported to induce switches to parallel G4 topology from antiparallel or hybrid structures 






single stranded nucleic acids in metal-free conditions. Examples 
of the former appear to be more elusive, perhaps because of the 
additional barrier to override the conformational preference 
exerted by the metal cation. However, the latter is more relevant 
for applications in physical conditions, where the concentration of 
metal ions cannot be readily controlled. Given the great number 
of G4 ligands reported to date, we have chosen to provide a 
conceptual overview, focusing on key examples that switch G4 
conformations between the three distinct types – parallel, hybrid 
and antiparallel. While there are no doubt more ligands than the 
ones we have highlighted that can induce such conformational 
remodelling, we believe the examples we have identified reflect 
the main concepts. 
2.2. Ligands that induces switches to parallel G4 folding 
One of the first examples of a ligand-driven conformational 
remodelling of G4 DNA was reported by Balasubramanian and 
co-workers in 2007.[94] Triamino-anthracene derivative 2 (Figure 
4) was designed to bind G4 by simultaneous π-π stacking 
interactions with the surface G-tetrads and threading of the side-
chain through the central channel of the G4 (Figure 5). The 
spacing of the amine groups was chosen to mimic the distance 
between K+ ions in the native G4, allowing the amine moieties to 
act as the channel cations when protonated at physiological pH. 
Interestingly, this ligand induces a conformational switch of the 
telo24 G4 from an antiparallel structure in sodium buffer to a 
parallel form (monitored by distinctive changes in the circular 
dichroism spectrum) in about two hours. Furthermore, since the 
previously reported porphyrazine ligand 12 (Figure 7, see Section 
2.3) preferentially stabilises the antiparallel form of telo24, the G4 
conformation could be toggled between antiparallel and parallel 
forms by sequential addition of the two ligands. However, the 
conformational switch was only reversed once in this manner; 
possibly further cycles were inhibited by an overaccumulation of 
the ligand fuel. 
Over the following decade, several further chemotypes capable of 
over-riding topological preference in favor of parallel G4 folds 
have been identified. For example, carbazole ligand BPBC (3, 
Figure 4) appears to induce telo22 to adopt a parallel fold in 
potassium buffer, rather than the usual hybrid-type G4 formed in 
such conditions.[95] For this effect to be observed however, it was 
necessary to co-anneal the ligand/DNA system (by thermal 
denaturation followed by cooling). Little conformational change 
was observed when the ligand was added to the pre-annealed 
structure as was observed for anthracene 2. In this report 
however, the overall goal was the development of a fluorescent 
probe rather than the conformational switching of G4, with the 
conformational preference of the ligand appearing to be incidental 
rather than by design. Similarly, N-methyl mesoporphyrin IX (4, 
Figure 4), is able to induce the parallel structure in telo22 
(amongst other telomeric sequences) when the sequence is 
annealed in the presence of ligand in potassium buffer, but not in 
sodium (antiparallel G4) or lithium (unfolded G4) conditions.[96] 
The same transition is observed if the ligand is added after the 
annealing step, though the process takes significantly longer (30h 
after annealing versus 12h prior to annealing). Cousins, Searle et 
al. disclosed DR4-47 (5, Figure 4), an oxazole-based ligand that 
strongly induces a parallel G4 signature in telo22 under potassium 
conditions when up to 5 equivalents of ligand are titrated into the 
pre-formed hybrid G4 without the need to re-anneal the 
DNA/ligand complex.[97]  The same ligand also induces a striking 
switch from antiparallel to parallel G4 in Na+ buffer (Figure 6), 
observed by attenuation of the positive features at 240 nm and 
260 nm, and the emergence of a strong positive  
 
Figure 5: The reversible switching of telo24 DNA between 
parallel and antiparallel folds with anthracene derivative 2 and 
porphyrazine 12.[94] 
 
Figure 6: Circular dichroism spectral changes observed on 
titration of telo22 in sodium phosphate buffer with DR4-47 (5) 
showing apparent switch from the original antiparallel (black 
trace) to parallel topology. On adding increasing equivalents of 
ligand, the negative band at 260nm gradually disappears (red 
and blue traces) before a positive band at 265 nm (green) 
corresponding to the parallel fold appears. The final spectrum 
(grey) corresponds to addition of 5 equiv. ligand. Reproduced 
with permission from The Royal Society of Chemistry.[97]  






band at 265 nm. Though the degree of conformational 
perturbation at equilibrium is impressive, kinetic studies (that 
would provide insight into the time required for the switch to be 
observed) were not reported. Meanwhile, the Huang group 
identified an interesting structure-activity relationship in a series 
of quinazoline derivatives. Ligands of type 6 (Figure 4) were 
capable of inducing shifts towards a parallel topology in potassium 
conditions, whilst ligands lacking the southern benzene ring were 
not capable of exerting such effects.[98] Further structural studies 
would be welcome in this case to understand the origins of the 
structural perturbation. Similarly, the para isomer of BQ-OHEtP 
(p-7) developed by the same group could induce antiparallel 
structure of telo21 to form the parallel structure in the presence of 
sodium ions, but the meta isomer (m-7) did not have this 
activity.[99]  
 
Though the systems discussed above are of interest, the ability of 
the ligands to induce conformational switches in G4 DNA appears 
to have been discovered serendipitously in these cases, and the 
thermodynamic driving forces and mechanisms of the remodeling 
pathways are not fully understood. Furthermore, the new G4 
topology in these earlier studies is assigned primarily from circular 
dichroism data. Whilst the changes observed are consistent with 
the diagnostic features of parallel G4s (i.e. a positive band at ~ 
265 nm and negative band at ~ 240 nm),[11] this is not conclusive 
proof that a new topology has been generated. Indeed, the telo23 
G4 has recently been shown to adopt the same hybrid G4 fold in 
both potassium and sodium conditions, despite significant 
changes in the respective CD spectra that are suggestive of 
different folding topologies.[100] Whilst comparison to reference 
spectra can be seemingly convincing, interpretation of CD data of 
G4/ligand complexes is complicated by the often overlapping 
absorbance spectra of the G4 and the ligand, meaning that 
induced dichroism in the ligand spectrum (by binding to the chiral 
environment of the DNA) may perturb the apparent spectral 
signature of the nucleic acid structure. Care must therefore be 
taken before attributing a new folding topology to a G4 on the 
basis of CD data. These issues are addressed in work reported 
more recently by Wang and Chang, who employed a more 
rational approach towards the development of a ligand that 
induces a parallel G4 against the bias of the other folding 
conditions.[101] Here, the well-documented effect of polyethylene 
glycol (PEG) to induce parallel G4 folding, by molecular crowding 
effects, was applied in the design of a G4 ligand capable of 
exerting structural changes. A PEG moiety was conjugated to a 
G4-binding carbazole core bearing positively-charged pyridinium 
groups to create the ligand known as BMVC-8C3O (8, Figure 4), 
thereby translating the known solvent effect of PEG into a local 
ligand effect. The authors found that the ligand promotes a local 
dehydration effect induced by the close proximity of PEG to the 
G4 on ligand binding, disrupting the solvation of the G4 and 
favoring the parallel fold. Whilst no changes appeared to be 
induced in telo24 by ligand 8 at 25 °C, at physiological 
temperature (37 °C) the ligand induces conformational 
remodeling to the parallel structure in potassium buffer at the 
micromolar level in a matter of hours. As in previous examples, 
the changes detected by CD spectroscopy are convincing, but the 
authors provided further confirmation of their results through a 
more detailed structural study by NMR spectroscopy which 
proved the induction of parallel G4 by ligand 8.[102] The 
mechanism of interconversion was also investigated, with 
hydrogen-deuterium exchange studies demonstrating a local 
rearrangement took place rather than global unfolding of the 
quadruplex. More recently, Tan et al. have discovered that 
isaindigotone derivatives (e.g. 9, Figure 4) can induce parallel G4 
folding in the telo21 sequence in potassium buffer.[103] Though the 
initial discovery appears to have been unexpected, the group  
 
Figure 7: Ligands reported to induce switches to antiparallel G4 topology from parallel or hybrid structures. 






embarked upon a computational study to generate a 
pharmacophore model that predicts the ability of such derivatives 
to induce such conformational changes. Through this approach, 
a training set of twenty two derivatives from the group’s compound 
library generated a model that identified ten further putative hits 
from the wider library of over 5000 compounds. Pleasingly, all ten 
compounds were found to induce significant remodeling of telo21 
G4 to the parallel form in K+ rich conditions. Towards a similar end 
Ma, Nagasawa and co-workers recently employed a docking 
approach to identify compounds that bind more strongly to parallel 
form of G4, rather than the antiparallel form of the same sequence, 
with the aim of identifying ligands able to induce the parallel G4 
fold against the inherent presence of the metal cation.[104] The 
team began with previously reported macrocyclic hexaconazole 
cores, known to strongly stabilize G4, and modified them to 
incorporate four side chains to target the four grooves of parallel 
G4. The lead compound (10, Figure 4) was demonstrated by CD 
spectroscopy to induce the parallel G4 fold in telo24, bcl-2 and a 
thrombin aptamer in either sodium or potassium conditions. The 
switching process appears to be rather slow, requiring overnight 
incubation for the effect to be demonstrated with 5 equivalents of 
ligand, a factor that probably requires optimization before real 
applications can be realized. 
2.3. Ligands that induce switches to antiparallel or hybrid 
G4 folding 
In comparison to ligand-induced folding to parallel G4 structures, 
examples of ligands that drive switches to antiparallel or hybrid 
structures are seemingly rare. In 2005, the Hurley group reported 
that that telomestatin (11, Figure 7), able to induce the conversion 
of hybrid G4 to the antiparallel form in potassium buffer.[105] This 
appears to proceed without the need to re-anneal the DNA 
sequence in the presence of ligand. The porphyrazine derivative 
reported by Sanders (12, Figure 7) was previously introduced in 
Section 2.2 as a means to reverse the activity of anthracene 2 to 
regenerate an antiparallel G4 structure in telo24 DNA. Indeed, in 
a separate study, the ligand was shown to induce the formation 
of antiparallel G4 in the presence of potassium ions at 20 °C.[106] 
A similar effect was observed for azobenzene derivative 13 (see 
also Section 2.5) but again it is not clear how long this ligand takes 
to exert the conformational change.[107]  
 
As mentioned in Section 2.2, care must be taken to avoid 
overinterpreting the CD data without more detailed structural 
information to validate these conformational switches. As well as 
NMR-based methods, mass spectrometry offers a 
complementary means of probing ligand/G4 complexes, since 
ligand and cation binding stoichiometries can be measured 
simultaneously. Gabelica and co-workers used these methods to 
identify that classical G4 ligands 360A (14), PhenDC3 (15), and 
pyridostatin (16, Figure 7) induce changes in G-quadruplex 
folding topology.[108] All three ligands exerted changes in cation 
stoichiometry in telo22, telo23, telo24, telo26 DNA, observed as 
a shift from two to one K+ cation per G4, implying the presence of 
only two contiguous G-tetrads. CD results added further insight to 
these observations, revealing spectral features consistent with 
the emergence of an antiparallel folded structure upon ligand 
binding. 
Induction of hybrid G4 folding in metal-rich conditions appears to 
be even more elusive. Gray, Li and Chaires reported that 
porphyrin derivative  TMPyP4 (17, Figure 8), a widely studied G4 
ligand despite its poor selectivity for G4 over duplex DNA,[71] could 
induce the switching of telomeric DNA from basket to hybrid in 
sodium conditions as monitored through CD, though the switch 
was not driven to completion.[109] Meanwhile, the same ligand was 
shown to prompt changes in the CD spectrum of telo24 
corresponding to induction of an antiparallel topology (from the 
hybrid topology) in K+ buffer by Zhang et al.[110] 
 
 
Figure 8: Porphyrin ligand TMPyP4, reported to induce 
switches to hybrid and antiparallel G4 structures and also 
unfold certain G4 DNA and RNA structures. 
 
Figure 9: Ligands reported to induce unfolding of G4 
structures, see also Figure 8. 






2.4. Ligands that disrupt G4 folding 
Each of the ligands discussed above, based on the data reported, 
appear to cause changes to G4 topology whilst preserving the 
overall quadruplex structure. A final class of structures warrants 
discussion at this point: ligands that destabilise G4 folding and 
cause a denaturation of the structure. Again, these ligands appear 
to have been discovered serendipitously, and more rational 
approaches towards molecules that can exert these effects would 
be a welcome addition to the G4-ligand literature. 
The previously-mentioned cationic porphyrin TMPyP4 (17, Figure 
8) was discovered to disrupt G4 structure in a bimolecular 
quadruplex formed by the Fragile X FMR1 gene containing 
d(CGG) repeats. Indeed, the ligand decreased the meting 
temperature of the d(CGG)7 quadruplex by 14 °C at a 
concentration of 0.3 μM.[111]  More recently, Basu and co-workers 
demonstrated, by NMR and CD spectroscopy, that the same 
ligand unfolds the otherwise stable G4 found in the MT3 
endopeptidase mRNA sequence by NMR and CD spectroscopy 
at concentrations in the order of 10 μM. This effect appears to 
result in the upregulation of gene in HeLa cells.[112] Meanwhile, 
Waller, Balasubramanian and co-workers, discovered a 
triarylpyridine derivative capable of disrupting G4 in the c-kit 1 and 
2 G4 sequences during a research programme examining the use 
of this scaffold for the design of G4-binding agents.[113] 
Interestingly, though many molecules of this class were able to 
confer stabilisation to these G4 structures,[114] compound 18 
(Figure 9) was found to induced the unfolding the G4 at 
concentrations around 50 μM. This was initially detected by 
attenuation of the G4 bands in the CD spectrum upon titration with 
18, further verified by NMR-methods and (in a subsequent study) 
by atomic force microscopy.[115] The destabilising effect on G4 of 
compound 18 also appears to translate into an up-regulation of 
expression of the corresponding gene in live HCG-27 cells, 
suggesting a use for such compounds to probe the role of G4 in 
gene expression. These results also contribute further evidence 
towards the hypothesis that G4 targeting molecules could be 
exploited as therapeutics by modulating gene expression. 
Kaluzhny and colleagues later discovered an 
anthrathiophenedione derivative (19, Figure 9) that appears to 
unfold the sodium structure of telomeric DNA, since the 
perturbations observed in the CD spectrum of the G4/ligand 
complex match those generated when the sequence is unfolded 
by thermal denaturation.[116] For both 18 and 19, the nature of the 
binding site precise mechanism of unfolding remains unclear, and 
further studies in this area would be welcome to provide valuable 
insight towards the more rational design of G4 stabilizing agents.  
 
More recently, O’Hagan, Galan and co-workers identified a stiff-
stilbene derivative (20, Figure 9) that induces the unfolding of the 
hybrid sodium form of telo23.[55] This was a particularly surprising 
finding given that the same ligand stabilizes the potassium form 
of the same sequence. Molecular dynamics and metadynamics 
simulations, in addition to NMR studies, were employed to identify 
the likely binding site and mechanism of unfolding, suggesting the 
ligand targets the G4 grooves before intercalating the G4 
structure, which leads to eventual disruption of the hydrogen bond 
network of the G-tetrads. Whilst the finding that ligand 20 is  
 
 
Figure 10: (a) Reversible trans-cis photoisomerization of azobenzene-derived G4 ligands (b) photoinduced folding and unfolding 
of telo24 G4 monitored by CD (c) evidence of robust photoswitching of G4 folding by ligand 21 over several cycles by monitoring 
ellipticity at 265 nm. Reproduced with permission.[54] Copyright 2010, Wiley.  






capable of unfolding G4 structures under certain conditions was  
unexpected, it was deliberately designed with the intention of 
exploiting the photochemistry of the central stilbene scaffold as a 
means to control the spatiotemporal activity of the ligand using 
light as an external trigger, discussed in more detail in the 
following section. 
2.5. Ligands that permit stimuli-responsive G4 folding 
In the previous sections, we aimed to highlight the power of small 
molecules to go beyond simply stabilizing pre-formed G4 
structures and exert changes in the folding arrangements. The 
refolding of the G4 can be thought of as a primitive mechanical 
system fueled by the added ligand, hinting at possible applications 
in the development of nanodevices. However, it might be difficult 
to imagine such applications for many of the previously described 
systems since in most reported cases the switch is a one-way 
process. Clearly, a much more useful system for such 
applications is one that can be switched back and forth multiple 
times, allowing more robust on-demand control of the “on” and 
“off” states. Furthermore, it would be ideal if the system could 
demonstrate this response without the repeated addition of 
chemical fuels, instead showing responsiveness exclusively to 
external triggers. In this section we explore progress made 
towards this goal. 
 
2.5.1. Photochemical approaches 
 
The first example of a stimuli-responsive ligand designed to 
influence G4 folding was reported by Wang, Zhou and colleagues 
in 2010. An azobenzene-derived ligand (trans-21, Figure 10a) 
was found to induce G4-folding in the absence of cations in water 
in the trans form, whilst the cis isomer did not have such an 
effect.[54] This allowed a very interesting application to be 
developed in which G4 confirmation could be controlled with light 
by exploiting the photoisomerisation properties of the ligand, 
since the cis isomer can be generated from the trans by 
illumination with UV light. Furthermore, this process proves to be 
reversible by the subsequent exposure of the system to visible 
light. This allowed the unfolding and refolding of G4 to be cycled 
at least ten times without any appreciable photo-fatigue (Figure 
10b and 10c). In a follow-up study, the authors attempted to 
exploit this system in the presence of metal ions to mimic 
physiological conditions, those commonly employed in 
biophysical studies of G4s.[107] Unfortunately, ligand 21 was found 
to be ineffective in these studies. The authors do not specifically 
comment on why this system is adversely affected by the 
presence of metal salts, though perhaps the preference on G4 
folding topology induced by the metal cation is more difficult to 
overcome by ligand effects. This led the authors to develop further 
analogues of 21 (such as morpholino derivative 13, Figure 7) 
which appear to allow the photo-regulation of G4 topology in ionic 
conditions to some extent. However, as in previous cases, though 
response observed in the CD spectra is consistent with 
topological switching and appears to be reversible, full details 
about the nature of the ligand-induced structures are unclear. 
Additionally, the reversibility is not as robust as the original system 
in the absence of metal cations, with only three switches in 
topology achieved in these later cases. Photoswitchable 
chiroptical azobenzene-G4 complexes were have also been 
reported by the Matczyszyn group.[117] Though in these cases the 
formation and dissociation of the complex could be controlled by 
the photoisomerization process, the compounds appear to exert 
little effect on G4 topology and also appear to interact significantly 
with duplex DNA, perhaps indicated that applications of 
azobenzene derivates may be confined to situations where a high 
level of quadruplex/duplex selectivity is not required.  
 
Towards regulation of different G4 topologies in metal-rich 
conditions, Czerwinska and Juskowiak developed a series of 
photoswitchable arylstilbazolium G4 ligands (e.g. 22, Figure 
11).[118] Though these compounds were shown to bind with some 
selectively to different G4 topologies and isomerise between E 
and Z forms in sodium buffer, unfortunately the 
photoisomerization was inhibited in the presence of DNA. As 
introduced in Section 2.4, stiff-stilbene derivative 20 (Figure 9) 
induces the unfolding G4 DNA. Upon investigating the 
photochemistry of the ligand in these conditions, the authors 
found that a photooxidative reaction pathway dominates, rather 
than the E-Z isomerization observed for the Czerwinska ligands. 
This allowed the folded topology of the G4 to be regenerated by 
deactivation of the ligand by 400 nm light, and repeated cycling of 
unfolding/refolding was achieved by fueling the system with the 
photolabile ligand (Figure 12).[55] A key limitation of the system is 
of course the need for repeated additions of ligand fuel to drive 
the complementary photoresponse. Further efforts by the team 
are currently focused on optimizing the photochemistry of the 
ligand scaffold to produce a system that allows the full reversible 
photo-regulation of G4 folding. 
 
2.5.2. Host-guest approaches 
 
 
Figure 11: Arylstilbazolium ligands reported by 
Czerwinska and Juskowiak.[118] 
 
 






The further systems that are worthy of discussion here employ 
host-guest approaches to control the effect of ligands on G4 
folding. In the first, the Zhou group et al. employed the 
azobenzene derivative trans-21 (Figure 10a), observing that the 
terminal piperidinium cations have good affinity for cucurbit[7]uril 
(CB7, 23, Figure 13a) host.[119] Whilst free ligand trans-21 induces 
the formation of G4 (see above), sequestration by CB7 causes 
dissociation of the ligand from the G4 and concomitant unfolding 
of the DNA secondary structure occurs. By fueling the system 
alternately with CB7 23 and a competitive guest, 
(adamantylammonium 24) 13 switches of G4 unfolding and 
refolding were achieved. This system was applied to control the 
activity of the thrombin enzyme (Figure 13b). In this case, a 
thrombin binding aptamer containing a G4-forming linker (based 
on telomeric TTAGGG repeats) binds to and inhibits thrombin 
activity. The addition of trans-21 triggers the folding of the linker 
thereby causing the dissociation of the inhibitor, un-gating the 
 
Figure 12: reversible unfolding of G4 DNA using the 
photoresponsive stiff-stilbene 20. Reproduced with 
permission.[55] Copyright 2019, Wiley. 
 
 
Figure 13: (a) Chemical structure and cartoon representation of cucurbit[7]uril, an efficient molecular host for ammonium cations such 
as trans-21 and adamantylammonium 24. (b)  Switchable control of thrombin activity by exploiting the host-guest chemistry of G4 
ligand 21 and CB7 23.[119] 






activity of the thrombin. The enzyme can be subsequently 
deactivated by adding CB7 (23) which sequesters the ligand, 
causing unfolding of the G4 and regeneration of the 
thrombin/inhibitor complex. In the same way as the original proof-
of-concept outlined above, addition of adamantylammonium 
cation 24 reverses this process. Whilst the eventual utility of this 
system is perhaps restricted by the need for sequential addition 
of ligand fuels, it is an elegant proof-of-concept that 
supramolecular approaches can be used as a means to control 
G4-mediated processes and the possibility for further refinement 
is exciting. 
 
In a different approach, Monchaud, Mergny and colleagues 
exploited the response of well-known G4 ligand 360A (14, Figure 
7) to Cu2+ cations, which are also known to induce the unfolding 
of G4 DNA to a single-stranded form by preferential binding to the 
single-stranded structure.[120] The conformation of 360A can be 
switched from a crescent to linear geometry by the addition of 
Cu2+ cations (Figure 14), dramatically weakening the G4 affinity 
of the ligand. Whilst comparatively weaker ligands that do not 
display such an effect could successfully guard telomeric G4 
against Cu2+ mediated unfolding, 360A was unable to do so 
despite being a much stronger G4 ligand. Therefore, the switch in 
geometry of the ligand induced by Cu2+ is ultimately responsible 
for the unfolding of the G4/360A complex. The folding can be 
reversed by adding the chelating ligand EDTA to sequester the 
copper and regenerate both the G4 and the active conformation 
of 360A. The Clever group also recently reported a 
Cu2+/EDTA/ligand supramolecular system to control the binding 
of G4 DNA to thrombin.[121] In this case however it is necessary to 
pre-incorporate the required glycol-pyridine ligand into the 




The work discussed above demonstrates the potential of G4 
ligands to go beyond simply stabilizing a single G4 structure and 
exert control over G4 polymorphism. Interestingly, this survey 
shows a gradual emergence of studies concerned with the 
rational design of ligands capable of exerting such effects, for 
example by exploiting known solvent effects (e.g. BMVC-8C3O, 
8) or by using computational approaches (isoindigatone 9). 
Furthermore, reports have recently appeared that demonstrate 
how ligands responsive to external triggers may allow the 
development of stimuli-driven G4 systems, where such reversible 
control may allow the spatiotemporal modulation of mechanical 
work or reactivity to be controlled by G4-folding processes. 
However, for real-world applications to be realized, more robust  
and reversible regulation of such systems, particularly in the 
presence of metal ions that drive G4-folding in physiological 
conditions, is likely to be required. Additionally, further evidence 
of the exact nature, mechanisms, and kinetics of conformational 
switching would be welcome to allow the refinement of these 
systems and enable new applications to be imagined. 
 
3. Ligand-driven modification of G4 structure – 
toward new biological probes and 
therapeutics? 
 
All of the ligands discussed in the previous section rely on non-
covalent supramolecular interactions with nucleic acids to exert 
their effects. In this section we consider a complementary strategy 
– the deployment of G4-binding chemotypes to direct the selective 
covalent modification of the oligonucleotide structures. It is well 
known that biology itself relies on such a strategy for the 
epigenetic regulation of gene expression.[122] Partly inspired by 
this feat of natural engineering, selective covalent modification of 
nucleic structures has commanded a significant amount of 
research attention, whether to develop new biological tools[123] or 
to induce nucleic acid damage for therapeutic effect, with the well-
known anticancer drug cisplatin being a case in point.[124] 
However, obtaining selectivity for a particular DNA sequence is 
challenging, leading to unspecific labelling and off-target side 
effects.[124]  The precise three-dimensional structures of G4s, 
which sets them well apart from single-stranded and duplex 
nucleic acids, provides an opportunity to overcome these issues, 
since their distinctive binding sites allow the selective targeting of 
these structures with small molecules. As summarized in the 
sections below, developments in the field of G4 ligand design 
have indeed permitted the design of several G4-targeting agents 
to modify nucleic acid in a more selective manner, for example by 
metalation,[125] alkylation[126] or scission.[127] Furthermore, since 
guanine is the most readily oxidized DNA base,[128] it is not 
surprising that efforts have also been made to utilize G4 ligands 
as a mean to direct the site-selective modification of nucleic acids 
in this way.[82] The following sections explore the progress made 
in these areas.  
 
3.1. Metalation of G4 
 
 
Figure 14: Supramolecular regulation of the activity of 
ligand 14 G4 binding affinity and G4 folding using Cu2+ and 
EDTA.[120] 






A number of research programs have been directed towards the 
development of G4 ligands derived from metal complexes, where 
the highly electropositive character of the metal is able to confer 
strong binding affinity to the negatively charged DNA.[129–131] 
Given the known reactivity of nucleic acid bases with metal 
centers, such complexes also allow the possibility of covalent 
binding modes. Not only does this have the potential to strengthen 
the binding interactions themselves, but such a response could 
also be exploited to therapeutic ends, since the classical DNA 
damage induced by ligation to metals can be combined with the 
G4-specificity of the ligands over other nucleic acid structures to 
allow enhanced selectivity for particular nucleic acid sequences.  
 
In 2007 the Teulade-Fichou group reported the first example of a 
dual non-covalent/covalent G4 ligand, derived from a platinum-
quinacridine hybrid (25, Figure 15).[132] This molecule was 
designed to contain a G4-stacking motif with a linker that directs 
the Pt-warhead toward the opposite terminal tetrad or a loop  
residue (Figure 16). Indeed, by gel electrophoresis methods it was 
found that this compound platinates exclusively at the 5’ tetrad of 
the antiparallel telo22 sequence in sodium buffer, at the G2, G10 
and G22 residues. 
 
Figure 15: Ligands reported to direct the selective metalation 
of G4 nucleic acids. 
 
Scheme 1: G4-gated photoinduced dissociation of ruthenium complexes to generate reactive metalating species. [125] 
 
 
Figure 16: Directed platination of terminal G-tetrad residues 
of telo22 by ligand 25.[132] 






The denaturing gel assay found that the platinated adducts are 
stable, since they migrate through the gel in the complexed state. 
Whilst DNA platination usually occurs at the N7 site of guanine 
bases, these residues are protected in G4s by the Hoogsteen 
bonding arrangements of the G-tetrads, therefore suggesting that 
in this case metalation actually proceeds via the initial disruption 
of the terminal tetrad. Indeed, this hypothesis suggests that G4 
loops can be targeted preferentially to the G-tetrads, a goal which 
has since been realized experimentally. Rao and Bierbach 
observed that Pt-ligand 26 (Figure 16) primary reacts at loops 
regions of telo22 and telo24, metalating adenine residues at N1, 
N3 and N7 sites.[133] Though some metalation of guanine N7 sites 
was still observed, kinetic experiments found that adenine 
residues are attacked more quickly and that reaction with G4 is 
approximately two-times faster than with duplex DNA. The 
authors acknowledge that the limitations of the system were likely 
due to the relatively poor G4 intercalating power of the acridine 
functionality (more commonly employed as a groove-binding  
chemotype) and suggest optimization of this feature may improve 
the efficiency and selectivity of the platination reaction.  
 
More recently Bertrand, Teulade-Fichou and co-workers achieved 
exclusive platination of loop adenines in G4 with Pt-terpyrdine 
complexes.[134] With compound 27 (Figure 16), specific platination 
of A13 (35% yield) was observed in telo22 G4. In this case, the 
ligand is proposed to interact with the lower G-tetrad, thus 
directing platination to the adenine residue in the diagnonal loop. 
By monitoring the reactivity of the ligands with a duplex/G4 hybrid 
oligonucleotide model, the authors found that adenine platination 
dominated for G4 whilst guanine platination was more prevalent 
in duplex, with up to twelve-fold faster kinetics observed for the 
G4 sequence, a significant improvement on the previous systems. 
 
Meanwhile, the Glazer group have developed ruthenium-derived 
complexes that promote the covalent metalation of G4, for 
example complexes 28 and 29 (Figure 15).[125,135] In these cases, 
the ortho methyl groups on the dipyridophenazine (dppz) 
functionality add steric strain to the system which promotes the 
photo-induced ligand dissociation to generate active metalating 
complex 30 and free ligand 31 (Scheme 1). Interestingly, whilst 
the ligand is relatively unreactive in water, it becomes an order of 
magnitude more reactive in the presence of DNA and is 3-fold 
more reactive when complexed to G4 DNA versus calf-thymus 
DNA. In these ligands, the lower energy ‘‘dark’’ state that arises 
from metal-to-ligand charge transfer to the phenazine portion of 
the dppz functinality, whilst the higher energy ‘‘bright’’ state results 
from charge transfer to the bipyridine portion of the ligand. Whilst 
aqueous environments lower the energy of the ‘‘dark’’ state, in the 
presence of DNA the bright state is more thermally accessible 
which essentially activates the observed photochemistry. 
Subsequently, the group reported halogenated analogues of type 
29 were reported, which appear to have better selectivity for G4 
over duplex DNA.[135] 
3.2. Alkylation of G4 
Though strategies for the covalent modification of nucleic acids 
have long been known,[137] the possibility of conjugating alkylation 
warheads to known G4-binding chemotypes to improve their 
selectivity has only been explored over the past decade or so as 
the field of G4 ligand design reached sufficient maturity to allow 
the more specific targeting of these structures. Interestingly, not 
only has selective alkylation of G4 in the presence of duplex DNA 
 
Figure 17: Ligands reported to alkylate G4 under thermal 
conditions 
 
Scheme 2: General mechanism of DNA alkylation by in 
situ generation of quinone methides from aromatic 
Mannich bases.[136] 






been achieved, which is clearly necessary for G4-targeted 
applications in biological circumstances, but certain classes of 
compound also allow for the stimuli-driven triggering of the 
alkylation events, allowing an additional level of spatiotemporal 
control. 
 
3.2.1. Thermal alkylation 
 
An early study hinting at the possibility of using G4 ligands as the 
basis to improve the selectivity of nucleic acid alkylating agents 
was reported in 2006 by Tan et al. The authors demonstrated the 
G4 selectivity of compound 32 (Figure 17) derived from porphyrin, 
a known G4-binding chemotype.[138] Previously the compound 
exhibited toxicity in cervical cancer (HeLa) and liver cancer 
(HepG2) cells under photoirradiation, an effect tentatively 
attributed to the photoinduced formation of quinone methides (37) 
and subsequent alkylation DNA (Scheme 2). However, it is 
unclear whether any such alkylation is G4 specific, or whether the 
toxic effects instead result from the generation of singlet oxygen 
(see Section 3.3).  
 
Since then however, significant progress has been made towards 
the development of thermally activated G4-selective alkylating 
agents by the Freccero group. Following earlier work examining 
the potential of quinone methide precursors as general DNA 
alkylating agents,[139] the group exploited naphthalene diimide 
(NDI) derivatives to confer G4-selectivity to this warhead.[136] NDIs 
have themselves been extensively explored as G4 binding 
agents,[140] displaying impressive selectivity and, more recently, 
promising results against in vivo disease models.[141,142] Initially, 
the group reported compound 33 to be capable of alkylating 
telo22 G4. Generation of the active quinone methide required 
thermal activation (40 °C) in the buffered conditions required for 
the folding of the quadruplex. Under such conditions, 15% 
alkylation was observed (by denaturing gel electrophoresis) at 2 
μM drug concentration after 24 h incubation and the products 
were determined to be stable up to 70 °C. Interestingly, the length 
of the alkyl linker between the NDI and the alkylating warhead was 
critical, with shorter or longer chains than the propyl chains in  
compound 33 resulting in comparatively lower alkylation yields. 
Most critically, the selectivity of the system for G4 DNA was 
demonstrated, with alkylation of duplex DNA or single stranded 
DNA being substantially lower under comparable conditions. In a 
subsequent study, a secondary generation of compounds were 
introduced, where the quaternary ammonium functionality was 
replaced by an additional alcohol group (e.g. compound 34, 
Figure 17), since the former was considered unsuitable for cell-
based applications owing to its permanent cationic charge.[143] In 
this case, a more electron-rich aromatic system was necessary to 
allow the compounds to generate the active quinone methide 
species at 40 °C, given the neutral nature of the leaving group. 
16.8% alkylation of telo22 was achieved in 24h, comparable to 
the alkylation yields observed with compounds of type 33. At 
higher ligand concentrations, two alkylation events per G4 could 
also be observed. Compounds of type 37 appeared to be more 
selective for G4 than those of the first generation, with the 
compound concentration required for alkylation to be observed 
being 100 to 1000 times lower for G4 than single stranded DNA 
(scrambled telo22) and duplex DNA respectively. Though putative 
alkylation sites were identified by enzymatic digestion, 
unambiguous assignment remained elusive owing to the 
reversible nature of the adduct formation at higher temperatures. 
  
These issues were later overcome by the development of a third 
generation of compounds (35, Figure 17), which exploit the 
electrophilic character of oxiranes to promote irreversible 
alkylation.[80] Not only does compound 35 exhibit high selectivity 
for G4 (16% adduct formation G4 versus < 2% alkylation of single-
stranded and double-stranded DNA under comparable 
conditions), the adducts were shown to be significantly more 
stable than the quinone methide variants, allowing more detailed 
analysis of adduct formation by mass spectrometry. This revealed 
selectivity for the adenine residues of the G4, which contrasts with 
the usual selectivity for alkylation at guanine (Figure 18). 
 
 
Figure 19: Ligands reported to alkylate G4 under 
photochemical conditions 






3.2.2.  Photochemical alkylation 
 
Both the quinone methide and oxirane approaches to G4 
modification rely on thermal activation of the system to trigger 
alkylation events. Though this requirement has the potential to 
allow a degree of control on the system, the relatively mild 
temperature required is unlikely to serve as an ideal handle to fulfil  
this purpose. In contrast, light has several distinct advantages as  
a trigger for chemical processes, since it can be delivered with a 
much higher degree of precision in terms of location, intensity and 
time. 
 
The Teulade-Fichou group recently deployed the high G4 
selectivity of the bisquinolinum pyridodicarboxamide scaffold in 
the development of a series of photo-trigged G4 alkylating agents 
(e.g. compounds 39 and 40, Figure 19).[126] Their strategy relies 
on the conjugation of a known G4-binding chemotype to a moiety 
that releases the alkylating species  upon exposure to UV light. In 
the case of compound 39, the photoexcited state of the 
benzophenone can react with unsaturated systems to produce 
adducts in a [2+2] fashion, whereas the azido derivative 40 
generates a highly reactive nitrene species upon photoirradiation. 
Alkylation yields of 20-36% were achieved at a concentration of 
25 μM ligand, depending on the nature of the G4 topology. As 
observed for the quinone methide compounds of Freccero,[136] 
alkylation yield was significantly dependent on the nature of the 
spacer between G4-binding core and alkylating warhead, with the 
authors arguing that a more hydrophilic spacer allows the ligand 
to interact more closely with the hydrated DNA structure in 
solution. However, a slightly increased in alkylation yield appears 
to come at the expense of selectivity. For example, compound 40 
is a more effective alkylating agent of the K+ quadruplex (36% 
yield) than compound 39 (26% yield), but whilst the presence of 
an excess of single-stranded DNA competitor significantly inhibits 
alkylation of G4 by azide 40 (by approximately 40%), the activity 
of benzophenone 39 against G4 is unperturbed by the addition of  
the same competitor. Through a combination of sequencing 
methods, the predominant alkylation sites were identified as the 
loop thymidines (T6 and T11) for compound 39 and external G-
tetrad (G10 and G14) for compound 40. All compounds displayed 
photo-triggered cytotoxicity against breast cancer (MCF7) and 
lung cancer (A549) cell lines, whilst remaining non-toxic in the 
dark. 
 
Perhaps a key drawback to the application of compounds of type 
39 and 40 in biological applications is the wavelength of light 
required to initiate the photochemical reactivity. For both 
compounds, UVA (330-365 nm) radiation is required, which is  
toxic to cells and also suffers from poor tissue penetration, limiting 
its use in in vivo settings. Towards addressing these limitations, 
Freccero et al. exploited the optical properties of the NDI core 
towards the development of a photoreactive G4 ligand that can 
be triggered by green light (41, Figure 19).[145] This approach 
relies on the absorbance of (λmax = 532 nm) of the NDI 
chromophore and the subsequent generation of a highly reactive 
phenoxide radical by an intramolecular electron transfer process 
from the Mannich base to the triplet excited state of the NDI. 
Indeed, at 12.5 μM concentration of compound 41, 63.7% 
alkylation yield was obtained, significantly higher than previously 
achieved, with only trace amounts of alkylation observed for non-
G4 single-stranded or duplex DNA. In addition to mass 
spectrometry analysis, the group synthesized several mutant 
analogues of telo22 identify the precise modification sites in 
combination with digestion assays, demonstrating alkylation 
preferentially occurs at T12 and T6, in agreement with previous 
 
Figure 18: Irreversible alkylation of G4 with oxirane-NDI 
ligand 35.[80] 
 
Figure 20: Ligands reported that promote the selective 
scission of G4. 
 
Scheme 3: Proposed mechanism of formation of reactive 
metal-bound hydroxyl radicals by Cu-ATCUN ligands.[144] 






reports that phenoxide radicals preferentially target thymidine 
nucleobases.[146] 
3.3. Scission of G4 
The goal of the approaches discussed in the previous section is 
to essentially add non-native functionality to G4, whether metallic 
or organic species, with the ultimate goal of DNA damage or 
selective labelling. In contrast, the selective cleavage of G4 
structures has also been demonstrated in a small number of 
cases. Yu, Han and Cowan conjugated a Cu2+ binding moiety, an 
amino-terminal copper/nickel binding (“ATCUN”) to acridine-
based G4 ligands to promote selective cleavage of G4 sequences 
(compound 42, Figure 20).[147] Through mechanistic studies on 
related compounds in redox environments, it appears that the 
copper is involved in the generation of reactive oxygen species, 
such as the hydroxyl radical, with the distinction that they remain 
bound the copper rather than diffusing freely in solution. 
A possible mechanism is shown in Scheme 3, in which two-
electron reduction of O2 generates hydrogen perioxide leading to 
a subsequent Fenton-like reaction that results in the generation 
of a copper-bound hydroxyl radical. This reactive species may 
abstract hydrogen atoms from the DNA backbone leading to 
subsequent scission of the oligonucleotide strand.[144] Such 
observations go some way towards explaining the selectivity of 
the acridine-ATCUN conjugates for specific DNA sequences, 
where the G4-targeting fragment is responsible for bringing the 
reactive warhead close to the target site. Predominantly telo22 
was cleaved at A1 (12.8%), G2 (10.2%), T6 (13.7%) and A7 
(7.6%) sites. Subsequently, Freccero et al. developed NDI variant 
43 (Figure 20) which cleaves telo22 G4 specifically at A7−G9, 
A13−G15, and A19−G21 sites, whereas significantly less (and 
non-specific) scission was observed for single-stranded and 
duplex DNA under comparable conditions.[127] In this case, the 
authors undertook NMR and computational studies which found 
that ligand binding sites were consistent with cutting sites, 
potentially allowing the development of further analogues that 
could provide complementary scission patterns.  
3.4. Oxidation of G4 
Guanine has the lowest redox potential of the nucleic acid bases 
and is therefore the most susceptible to oxidation. The occurrence 
of such modifications in vivo leads to a variety of downstream 
effects. For example, the syn conformation of 8-oxo-guanosine 
may form Hoogsteen bonds to adenine rather than the usual 
Watson-Crick bonds to cytosine, leading to errors in DNA 
transcription.[128]  Indeed, potential protective roles of G4s against 
such oxidative DNA damage have recently been explored.[150] 
 
Given the over-representation of guanine in G4 forming 
sequences and the ability to target these sequences with ligands, 
it is unsurprising that groups have made efforts to develop tools 
for G4-targeted oxidation. Two possible pathways of oxidation of 
a guanine base are known.[128] Either singlet oxygen (generated 
by photosensitisation) may react directly with a guanine residue, 
generating 8-oxo-guanine 45 or spiroiminodihydantoin 46 
(Scheme 4). Alternatively, the photoinduced metal-to-ligand 
charge transfer (MLCT)  states of the complexes by may promote 
in photoinduced electron transfer (PET) and abstract an electron 
from the base to generate a guanine radical cation (Scheme 5) 
leading to subsequent adduct formation between the oxidized 
base and one of the metal ligands to generate products of type 47 
(Figure 21). The following sections consider strategies for G4-
targeted oxidation that exploit these complementary reactivities. 
 
3.4.1. Photogeneration of singlet oxygen 
 
Porphyrins are widely known to be efficient photosensitizers of 
oxygen.[151] Indeed, classical G4 ligand TMPyP4 (17, Figure 8) 
has been shown to promote the photocleavage of DNA 
sequences shown to prove more toxic to ovarian tumor cells 
irradiated with light than to cells kept in the dark, suggesting a 
mechanism of action involving the photogeneration of singlet 
oxygen and pointing to applications of G4 ligands in targeted 
photodynamic therapy.[152]  However, since TMPyP4 is known to 
also bind duplex DNA sequences,[71] it is unlikely to target G4 
genomic regions with the high specificity likely desired in 
therapeutic application. Furthermore, earlier studies suggested 
TMPyP4 induces photocleavage of the DNA strand meaning the 
reactive oxygen species presumably pursues more complex 
 
Scheme 4: Oxidation products of guanine generated by 
reaction with singlet oxygen.[128] 
 
 
Scheme 5: Mechanism of generation of guanine radical cations 
by photoinduced electron transfer from Ru-TAP complexes.[148] 
 
Figure 21: Adduct formed by the recombination of oxidized 
guanine radical cations and reduced Ru-TAP complexes.[149] 






pathways than those presented in Scheme 4.[153] Meanwhile, 
naphthalene and perylene diimides, both known to serve as 
effective scaffolds in selective G4 ligand design, have also been 
demonstrated to be effective photosensitizers of oxygen. Dinçalp 
et al. reported perylene/pyrene derivative 48 (Figure 22) which 
generates 1O2 with a high (93%) quantum yield and binds G4 with 
good affinity (Ka = 106 M-1), suggesting such compounds may 
allow G4-targeted photodynamic therapy.[154] Subsequently, 
Freccero et al. reported NDI analogues of type 49 could produce 
respectable quantum yields of 1O2 in the phototherapeutic (600-
800 nm) window.[155] Sciscione, Manet et al. also reported a series 
of magnesium(II) and zinc(II) porphyrazines 50 that bind G4 and 
generate singlet oxygen upon photoirradiation. However, in all of 
the above cases, the application of the molecules as tools to 
introduce G4-specific oxidative lesions does not yet appear to 
have been explored.  
 
More recently however, Beniaminov, Kaluzhny and co-workers 
disclosed tetracarboxymethyl porphyrin 51 which binds with 
preference to potassium hybrid G4s and returns distinctive 
oxidation patterns of guanine bases upon photoirradiation.[82] 
Interestingly, the oxidation footprint is found to depend on the G4 
conformation. For example, in the hybrid G4 form, oxidation of G9, 
G15, G21 and G3 dominates, whilst under conditions that 
promote the parallel fold oxidation primarily occurs oxidation at 
additional residues G11 and G17. This suggests that this system 
could be used as a tool to diagnose G4 folding topologies. Unlike 
other photosensitizers (e.g. TMPyP4, previously discussed), it 
appears the ligand primarily generates G-specific oxidative 
lesions (8-oxo-G and spiroiminodihydantoin) rather than non-
discriminate strand cleavage. Interestingly the light-triggered 
guanine oxidation was found to convert hybrid and parallel G4 
topologies to the antiparallel structure based on distinctive 
changes in the CD data (see Section 2). Critically, the system 
exhibits a degree of selectivity, with both hybrid and parallel telo23 
G4s found to be more susceptible to oxidation than double-helical 






3.4.2. Photoinduced electron transfer 
 
The second possible pathway of guanine oxidation is exemplified 
by certain ruthenium complexes and shown in Scheme 5. The 
design of these ruthenium complexes differs from the compounds  
discussed in Section 3.1 (designed to generate nucleic acid 
metalating agents upon photoirradiation) in that they exploit the 
electronics of the tetraazaphenanthrene (TAP) ligand, rather than 
the classical phenanthroline ligands, to promote photoinduced 
electron transfer leading to the generation of guanine radical  
cations.[148] In these Ru-TAP complexes, the triplet excited metal-
to-ligand (MLCT) charge transfer state is strongly oxidizing, 
sufficiently so to abstract an electron from a guanine base with 
concomitant generation of the reduced metal species. 
Subsequent recombination of the oxidized base and the reduced 
complex forms adducts of type 47. This reactivity has been 
demonstrated with guanosine monophosphate, and later applied 
in attempts to engineer systems that target G4 DNA due the over-
representation of guanine in these motifs. 
 
 
Figure 22: G4 ligands reported to promote the photogeneration of singlet oxygen. 






In effort to confer additional G4 selectivity to Ru-TAP complexes, 
the Elias group conjugated a known G4 binding chemotype, 
chlorophenylimizdazophenanthroline (CPIP), to the Ru-TAP 
center (52-55, Figure 23).[81] Several approaches to introduce  
the TAP functionality were pursued, including by modifying the 
CPIP ligand itself to include the pyrazine functionality (53), by 
employing TAP ancillary ligands (54), or by combination of both 
strategies (55). The control ligand (52), containing only 
phenanthroline ligands and no TAP functionality, did not promote 
oxidation, observed as an increase in ligand luminescence on 
DNA binding (indicating the excited state is not quenched by an 
oxidative process). Similar results were obtained when the TAP 
functionality was incorporated only in the CPIP ligand (53). 
However, when ancillary TAP ligands were used (54), the 
oxidative pathway was observed via quenching of the 
luminescence of the MLCT excited state. Pleasingly, the affinity 
of the compounds was 10-50 times higher for G4 than duplex 
DNA, suggesting adding known G4-targeting functionality 
successfully confers selectivity to these complexes. The 
complexes also demonstrated photocytotoxicity in cellular studies. 
However, whilst complexes 52-54 could possibly act via the PET 
pathway, compound 55 was also active, suggesting such 
photocytotoxicity may result from the generation of reactive 
oxygen species instead or, or in addition to, PET. 
 
Complexes containing two metal centers offer the possibility of 
multiple oxidation events by the same ligand, which may lead to 
DNA cross-linking. This approach was proposed by Mesmaeker 
and co-workers as a means to “freeze” the G4 conformation,  
leading to the design of complex 56 (Figure 24).[149]   This 
dinuclear ruthenium species demonstrated a similar affinity for G4 
and duplex DNA, (Ka in the order of 106 M-1) however 
photoreaction with telomeric G4 was more rapid. Electrophoresis 
methods demonstrated that ligand/G4 adducts were generated 
with up to 6:1 stoichiometry. Though further experiments including 
mass spectrometry on the purified adducts confirmed the nature 
of addition (analogous to Figure 21), it was not possible to 
demonstrate with certainty that crosslinking between two G bases 
had been achieved. In a more recent studies by the Thomas 
group, related pyrazine compounds were synthesized (57 and 
58).[156] In this example, the phenanthroline variant (58) was non-
emissive in water but bright MLCT luminescence was induced 
upon DNA binding. Again, by switching to TAP ligands on the 
metal (compound 58) the ligand promotes the guanine oxidation 
pathway. The compound also displays high photocytotoxicity in 
cells. However, like the Mesmaeker compound (56), G4/duplex 
discrimination is poor, suggesting that incorporation of G4-
targeting functionality (using a similar approach to Elias and 






Figure 23: Ruthenium complexes reported to promote the 
oxidization of guanine bases by photoinduced electron 
transfer. 
 






The work discussed in this section clearly demonstrates that 
significant attention is devoted towards directing the specific 
covalent modification of G4 nucleic acids through a variety of 
strategies. Indeed, the hypothesis that G4-targeting ligands can 
be employed to confer selectivity to classical warheads (such as 
platinum complexes) appears to be attractive and shows 
significant promise. Some encouraging selectivity in nucleic acid 
modification has already been observed for such compounds, 
including between G4 and duplex/single-stranded DNA (e.g. NDIs 
33-35), between different DNA bases (e.g. 25) and interestingly, 
between different topologies of G4 (e.g. 51). Furthermore, it is 
also promising that the cytotoxicity in cells of several of these 
compounds can be triggered by exposure to light, in a photo- 
dependent manner. However, in many cases, the selectivity for 
particular nucleic acid sequences and structures likely requires 
further optimization to allows such molecules to serve as robust 
biological tools or therapeutic agents. A significant number of G4-
targeting chemotypes remain to be explored for such purposes,  
leaving plenty of room for further development. The in vivo  
mechanism of action of such compounds would also benefit from 
further exploration to guide the development and optimization of 
G4-targeted photo-oxidative therapies.  
 
 
4. Caged G4 ligands – in situ activation for 
targeted therapy? 
Finally, we turn our attention to the concept of caged G4 ligands. 
These ligands are designed to remain dormant until their G4 
binding is activated by a situational stimulus. Unlike the previous 
examples of responsive ligands considered in this review, these 
ligands have their G4 binding functionality masked from the outset 
and thus they are worthy of consideration in a separate section. 
These ligands offer interesting potential applications, such as in 
the design of G4-targeting prodrugs whereby binding to nucleic 
acids can be activated specifically in tumor cells with the aim of 
generating more specific pharmacologies. 
 
4.1. Photocaged ligands 
 
In 2012, the Nagasawa group reported the first example of a 
photocaged G4 ligand, the macrocyclic polyoxazole ONv-59 (note 
the similarity to the G4 binding drug telomestatin).[157] whereby the 
G4-binding activity is neutered by the presence of the nitroveratryl 
(Nv) group which can be removed in a quantitative yield in 30 
minutes simply by photoirradation with 365 nm light. Indeed, 
FRET melting assays demonstrated the deactivation of G4 
binding by the caging group, with ONv-59 stabilizing G4 by only 
4.0 °C and the unprotected form stabilizing by 16.6 °C. Indeed, 
gel electrophoresis showed that no DNA ligand complex was 
 
Figure 24: Photocaged ligands for G4. The active form of 
the ligand is generated by in situ removal of the protecting 
group by irradiation with 365 nm light. 
 
Figure 25: A redox-activated G4 ligand. The Pt(IV) complex displays low G4 affinity but binding is restored by in situ reduction to the 
square-planar Pt(II) salphen species.[84] 






formed by ONV-59 and telo21 DNA in absence of light, but 
photoirradiation of the system for 30 min generated a new band 
corresponding to the DNA ligand complex, evidencing the 
photoactivation of the drug. Compound ONv-59 was also shown 
to be ineffective at inhibiting telomerase in the dark, but upon 
photoirradiation its activity was restored with potency comparable 
to the pure uncaged version. Significantly, whilst OH-59 was toxic 
to a range of cancer cells at the sub-micromolar level after a two-
day exposure, the caged version remained inactive unless 
administered in tandem with photoirradiation, though the results 
of the study do not unambiguously confirm the mechanism of 
action to be a result of light-activated G4 binding. 
 
 
The Balasubramanian group employed a similar strategy to cage 
the activity of pyridostatin, using again the nitroveratryl group to 
block one of the terminal amine residues (NHNv-60).[83] Like the 
Nagasawa compound ONv-60, the ligand can be quantitatively 
deprotected with UV light in 30 minutes. Again, the FRET assay 
confirmed that the caged ligand does not affect the stability of G4, 
but that G4 binding is restored to a level comparable to uncaged 
pyridostatin after irradiation for 30 min. Photo-dependent 
cytotoxicity was also observed for the compound, with the growth 
inhibition being very poor for the caged compound, and toxicity 
increasing in a time-dependent fashion, reaching the same level 
as pyridostatin after 30 min irradiation. Pleasingly, the authors 
also found the ligand effectively suppresses the expression of 
several G4-containing genes in live cells upon photodeprotection, 
whilst the caged version did not have such an effect. This 
suggests the mechanism of action of this compound could indeed 
be related to inhibition of gene expression by G4 folding, in a 




4.2. Redox caging 
 
A final example of a caged G4 ligand, provided by Vilar and co-
workers, is particularly interesting since it uses the redox and co-
ordination state of the metal to activate its G4 binding activity. The 
team developed a novel synthesis of platinum(IV) salphen 
complex 61 by oxidizing the corresponding platinum(II) precursor 
(62) with a hypervalent iodine reagent.[84] In the oxidized state, 
compound 61 has poor affinity for G4, possibly because of 
disruption of stacking interactions by the axial chloride groups. 
However, the compound is readily reduced to the platinum(II) 
species by glutathione and ascorbic acid, both common reducing 
agents in vivo. Pleasingly, the square planar complex has good 
affinity (Ka in the order of 105 M-1) for G4 DNA. These results 
suggest that analogues of 61 may display interesting toxicity for 
hypoxic cancer cells, owing to their reducing environment. It will 
be interesting to see whether this exciting application can be 
realized to achieve selectivity in different tumour types 




Given the ever-growing quest to develop more specifically 
targeted therapies through pro-drug strategies, it is encouraging 
to see initial progress towards this area in the field of G4-ligand 
design, despite the fact that such molecules have yet to reach the 
stage of clinical application. Light has again emerged as a favored 
trigger for the activity of particular G4 ligands, however, whilst light 
does indeed offers significant advantages over chemical stimuli, 
the challenges associated with its clinical use, its deliverability in 
vivo remain to be fully demonstrated in a wide range of situations. 
In the examples described above, the wavelength of light required 
to uncage the ligand is incompatible with in vivo application due 
to poor tissue penetration. Thus, given these current limitations, it 
is encouraging to see the emergence of complementary 
strategies for the in situ activation of G4 ligands that could be 
exploited towards therapeutic ends in the Pt-salphen complexes 
that may be activated by reducing environments, suggesting 
applications in hypoxic tumors whereby the trigger is endogenous 
rather than externally administered. All of these systems can 
surely be optimized and no doubt many further opportunities to 
control the in situ release of G4-targeting pro-drugs will be 
developed in due course. 
 
5. Summary and outlook 
The past two decades have seen great strides in G4 ligand 
development. From Hurley and Neidle’s seminal work on the 
discovery of a G4 ligand that efficiently inhibits the enzyme 
telomerase,[158] the first decade of G4 ligand development 
focused largely on optimizing G4 affinity and achieving 
discrimination against duplex DNA binding of such chemotypes. 
Impressive results have been obtained through these research 
programs leading to the emergence of several lead scaffolds that 
find wide application in biological studies and that represent 
starting points for further development. Work continues apace in 
this area, especially geared towards the hitherto elusive goal of 
achieving a G4-targeting therapy in the clinic. In the course of this 
review however, we have attempted to look beyond the use of G4 
ligands simply to stabilize G4 structures and examine what else 
they might achieve towards realizing both clinical and non-clinical 
applications. This reveals significant progress over the past ten 
years that clearly demonstrates additional and wide-ranging 
opportunities for control of G4 by small-molecule ligands. We 
have considered how ligands are capable of over-riding innate 
topological preferences to perform mechanical work or control 
reactivity in response to external stimuli. Next, we have examined 
how G4 ligands can confer selectivity to warheads that promote 
the modification of nucleic acids, and finally we have summarized 
progress towards the development of G4-targeting pro-drug 
candidates. Through this perspective, we have highlighted the 
opportunities and challenges such approaches provide towards 
the functional applications of G4 ligands. Whilst significant 
progress has been made in these areas, further opportunities 
remain to optimize such systems to fulfil their potential 
applications as therapeutics and it is our hope that this review will 
encourage new researchers to enter these fields. Finally, we hope 
that by bringing together the key literature on these topics 
together, new approaches to deploying G4 ligands for a range of 
applications will be identified. We look forward to following the 
progress of this exciting field in the coming years. 
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G-quadruplex (G4) ligands can do much more than simply associate with nucleic 
acids in a straightforward host-guest fashion. This review examines what else can 
be accomplished with G4-targeting molecules and considers the opportunities and 
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